MINNEAPOLIS / Jan 17, 2024 / Business Wire / Bright Health Group, Inc. (“Bright Health” or the “Company”) (NYSE: BHG) today announced that it has adopted NeueHealth as its corporate brand name. This reflects the Company’s ongoing focus on its NeueHealth business, which will continue driving long-term sustainable growth of its value-driven, consumer-centric care model, thereby increasing access to high-quality healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid. The Company’s common stock will begin trading under the new ticker symbol “NEUE” on the New York Stock Exchange (NYSE), effective January 29, 2024.
“Taking the NeueHealth name signifies our commitment to delivering value through our differentiated care model that uniquely aligns the interests of health consumers, providers, and payors,” said Mike Mikan, President and CEO of NeueHealth. “Our NeueHealth identity has been a core and successful part of our organization’s story, and we look forward to building on its strong performance as we take the lead in the industry’s shift to value-based care.”
NeueHealth currently serves more than 500,000 health consumers and partners with more than 3,000 affiliated providers across the country. NeueHealth consists of two segments, NeueCare and NeueSolutions, each focused on creating a seamless, coordinated care experience that maximizes value for health consumers, providers, and payors.
NeueCare
delivers value-driven healthcare to health consumers across the ACA Marketplace, Medicare, and Medicaid through owned clinics and partnerships with affiliated providers across the country. NeueCare takes a consumer-centric approach, developing a true relationship with patients early in their healthcare journey to deliver a high-quality, personalized care experience.
NeueSolutions
enables independent providers and medical groups to succeed in performance-based arrangements through deep financial alignment, customized population health tools, and strong partnerships with leading health plans and government programs, including participation in the Centers for Medicare and Medicaid Innovation’s (“CMMI”) ACO Realizing Equity, Access, and Community Health (REACH) program.
The Company will also relocate its corporate headquarters from Minneapolis to Doral, Florida. NeueHealth has had a strong presence in Florida through its Centrum Health, AssociatesMD, and Premier Medical Associates clinics, which have operated in the state for more than 20 years and serve more than 150,000 health consumers in Florida. The relocation underscores NeueHealth’s commitment to advancing its value-driven care model and deepening its presence in the local communities it serves. The relocation will not impact jobs in Minneapolis, where the Company will continue to operate certain corporate and administrative functions.
Branding across the Company will be transitioning over the coming months.
About NeueHealth
NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare ecosystem. For more information, visit: www.neuehealth.com.
Forward-Looking Statements
Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; our ability to comply with the terms of our credit facility, including financial covenants, both during and after any waiver period, and/or obtain any additional waivers of any terms of our credit facility to the extent required; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down our IFP businesses and MA businesses outside of California, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our businesses offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our Care Partner’s abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to accurately estimate our medical expenses, effectively manage our costs and claims liabilities or appropriately price our products and charge premiums; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage the growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to the new risks associated with our ACO Reach businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading “Risk Factors” in the Company’s reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.
Last Trade: | US$4.95 |
Daily Change: | 0.01 0.20 |
Daily Volume: | 1,595 |
Market Cap: | US$40.990M |
November 07, 2024 October 30, 2024 August 07, 2024 May 08, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB